कंपनी का अवलोकन
CRISPR Therapeutics AG is a prominent biotechnology firm dedicated to developing gene-based medicines for serious human diseases by utilizing its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, focusing on the creation of transformative therapies through advanced genetic editing technologies. As of the latest data, the company holds a market capitalization of $4.96B and reports an annual revenue (TTM) of $3.51M, with an employee count listed as N/A. The substantial market capitalization relative to the modest annual revenue suggests that the market is valuing the company primarily on its future pipeline potential and intellectual property rather than current profitability, indicating a high-growth biotech profile where revenue generation precedes commercial scale-up.
वित्तीय स्वास्थ्य
The company reported a revenue of $3.51M for the trailing twelve months, while the net income stands at -$581,598,976 and EBITDA is -$548,838,976. The significant disparity between the minimal revenue of $3.51M and the massive net loss of approximately $582 million reveals an extremely heavy cost structure typical of early-stage biotechnology firms, where research and development expenses vastly outweigh current sales. Free cash flow is reported at -$205,623,744, which indicates that the company is burning cash rapidly and lacks the immediate financial flexibility to sustain operations without external capital injection or successful commercialization of its therapies. The gross margin is 0.0%, the operating margin is -17912.5%, and the profit margin is 0.0%; these figures collectively indicate that the company is not yet generating positive returns on its sales, operating at a massive loss relative to its revenue base. In terms of solvency, the company holds $1.98B in cash against $206.75M in debt, resulting in a debt-to-equity ratio of 10.76, which suggests a highly leveraged balance sheet relative to equity, though the massive cash hoard provides a significant buffer against this leverage. The current ratio stands at 13.32, indicating an exceptionally strong short-term liquidity position where current assets significantly exceed current liabilities. Return on Equity is -30.2% and Return on Assets is -15.8%, revealing that management effectiveness in generating profits from shareholder equity and total assets is currently negative due to the heavy investment phase of the business model.
मूल्यांकन आकलन
The company has a P/E Ratio (TTM) listed as N/A and a forward P/E of -12.35, implying that earnings are currently negative and future earnings expectations are also not yet materialized in a positive manner. The price-to-book ratio is 2.58, which indicates that the market is pricing the company at a 158% premium over its tangible book value, reflecting high investor expectations for future asset appreciation and successful drug approvals. The price-to-sales ratio is exceptionally high at 1414.35, and the EV/EBITDA is -5.82; these alternative valuation metrics suggest that traditional profitability measures are irrelevant for this stage of the company, with valuation driven almost entirely by the perceived value of the pipeline and the CRISPR technology platform. The stock has seen significant volatility, with a 52-week high of $78.48 and a 52-week low of $30.52, meaning the current price sits within a wide range that reflects the speculative nature of the biotech sector. The beta value of 1.79 indicates that the stock price is highly volatile and tends to fluctuate 79% more than the broader market, signaling substantial risk for investors sensitive to market movements.
Growth & Income
Revenue growth year-over-year is -97.6%, while earnings growth year-over-year is N/A, indicating a contraction in revenue streams as the company transitions from earlier stages of development or faces commercial headwinds before achieving scale. Since there is no positive earnings growth to compare against revenue, the negative revenue growth implies a challenging commercial environment or a decline in the specific product sales currently contributing to the top line. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%; consequently, the company reinvests all available earnings and cash reserves back into research, development, and operational expansion rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue momentum and zero income distribution, highlighting a strategy focused entirely on long-term technology development rather than immediate financial returns or shareholder payouts.